Genus Company Overview, Contact Details & Competitors

Q: What is Genus's official website and social media links?

Genus's official website is genusplc.com. Genus has social profiles on LinkedIn.

Q: How many employees does Genus have currently?

Genus has approximately 1K employees.

Q: What technology does Genus use?

Genus's tech stack includes ISO/IEC 27001, Plyr, Apple iCloud Mail, Cookiebot Cookie Control, iCIMS.

Insights

Gathering insights about Genus…

Similar companies to Genus

Genus Tech Stack

Genus uses 8 technology products and services including IBM Planning Analytics, WordPress, Microsoft Excel, and more. Explore Genus's tech stack below.

IBM Planning Analytics
Business Intelligence
WordPress
Content Management System
Microsoft Excel
Editors
Angular
Javascript Frameworks
Java
Programming Languages
Google
Search Engines
Bootstrap
UI Frameworks
Cookiebot Cookie Control
Web Tools And Plugins

Media & News

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer,” i.
Dec 23, 2025 | www.businesswire.com
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Dec 04, 2025 | seekingalpha.com
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer. The session will be moderated by Garo Armen, PhD, Fo.
Nov 19, 2025 | www.businesswire.com
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (.
Nov 18, 2025 | www.businesswire.com
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
Nov 10, 2025 | www.zacks.com
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Fr.
Nov 10, 2025 | www.businesswire.com
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025. The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. Additional details regarding the webcast will be announced in the coming weeks. About Agenus Agenus is a leading immuno-.
Nov 05, 2025 | www.businesswire.com

Genus's Email Address Formats

Genus uses at least 1 format(s):

Genus Email Formats	Example	Percentage
First.Last@genusplc.com	John.Doe@genusplc.com	97%
FLast@genusplc.com	JDoe@genusplc.com	2%
First.Middle@genusplc.com	John.Michael@genusplc.com	1%

Frequently Asked Questions

What is Genus's phone number?

You can contact Genus's main corporate office by phone at

+1-608-846-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Genus's stock symbol?

Genus is a publicly traded company; the company's stock symbol is AGEN.

What is Genus's official website and social media links?

Genus's official website is genusplc.com and has social profiles on LinkedIn.

How much revenue does Genus generate?

As of December 2025, Genus's annual revenue is estimated to be $57M.

What is Genus's SIC code NAICS code?

Genus's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genus have currently?

As of December 2025, Genus has approximately 1K employees across 6 continents, including EuropeNorth AmericaAsia. Key team members include Head Of Group Financial Reporting: P. A.Founder And Chairman: G. B.Group Head Of Hr: S. B.. Explore Genus's employee directory with LeadIQ.

What industry does Genus belong to?

Genus operates in the Biotechnology Research industry.

What technology does Genus use?

Genus's tech stack includes IBM Planning AnalyticsWordPressMicrosoft ExcelAngularJavaGoogleBootstrapCookiebot Cookie Control.

What is Genus's email format?

Genus's email format typically follows the pattern of First.Last@genusplc.com. Find more Genus email formats with LeadIQ.

Insights

Similar companies to Genus

ADM

The Maschhoffs

JBS USA

Cargill

Smithfield Foods

Pilgrim's

Darling Ingredients

Tyson Foods

Seaboard Corporation

Perdue Farms

IOI - Loders Croklaan Oils

Agri Beef

CF Industries

Genus Tech Stack

Media & News

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Genus's Email Address Formats

Frequently Asked Questions

What is Genus's phone number?

What is Genus's stock symbol?

What is Genus's official website and social media links?

How much revenue does Genus generate?

What is Genus's SIC code NAICS code?

How many employees does Genus have currently?

What industry does Genus belong to?

What technology does Genus use?

What is Genus's email format?

Genus

Company Overview

Media & News

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?